We offer a comprehensive suite of antibody generation platforms designed to provide high-affinity, internalizing antibodies ideal for drug conjugation. Our focus on developability, internalization, and conjugation-compatibility ensures you receive antibodies ready for downstream functionalization and therapeutic development.
Antibody Discovery
Efficient and scalable antibody production is foundational to ADC development. Whether you are screening multiple candidates or generating large-scale material for conjugation and preclinical evaluation, Aurigene offers flexible expression platforms tailored to your project timeline and stage. From rapid transient expression for early-stage ADCs to stable cell line development for consistency batches, our upstream capabilities are designed to ensure high-quality antibody supply optimized for downstream conjugation and analytical success.
Transient Expression
- Rapid antibody generation using HEK293 or CHO systems
- Ideal for early-stage ADC screening and quick turnaround
- Typical yields: 50–400 mg/L (HEK); up to 1 g/L (CHO)
- Antibodies purified via Protein A, ion exchange (if needed), and SEC
Get high-purity antibodies ready for conjugation in just 2–3 weeks.
Stable Cell Line Development
- Generation of CHO-based stable clones for long-term, scalable production
- Clone screening based on titer, growth profile, and product quality
- High-yield fed-batch process with optimization of expression vectors and media
Consistency, scalability, and control for large-scale ADC programs
Downstream Purification for Conjugation Readiness
- Platform purification using Protein A, SEC, HIC, and IEX
- Endotoxin control, buffer exchange, and low aggregation guaranteed
- Analytical QC: SDS-PAGE, SEC, endotoxin, intact mass, and reduced mass
Ensures conjugation-grade antibodies with full lot release documentation
Why Choose Aurigene for Antibody Production?
At Aurigene, our antibody production is tightly integrated with the downstream bioconjugation workflow ensuring that every batch is not just pure, but conjugation-ready. We offer flexible production formats, rapid timelines, and quality control designed specifically for the unique needs of ADC development. Whether your program needs 1 mg or 1 g, our agile team and modular facilities can scale with your project without compromising on quality or timelines.
We offer:
CHO and HEK-based systems for flexible, rapid expression
Conjugation-optimized production workflows from day one
Experienced upstream and purification scientists with ADC focus
Full characterization support: Mass, DAR, aggregation, and endotoxin
Seamless integration with conjugation, analysis, and in vitro teams
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Connect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Methoxy Polyethylene Glycol (m-PEGs)
Aurigene Pharmaceutical Services is a leader in the synthesis of activated MethoxyPolyethyleneGlycol(m-PEGs), With a comprehensive product range and customized services. ...
Read More
Base mediated spirocyclization of quinazoline: one-step synthesis of spiro-isoindolinone dihydroquinazolinones
2020
A novel approach for the spiro-isoindolinone dihydroquinazolinones has been demonstrated from 2- aminobenzamide and 2-cyanomethyl benzoate in the presence of KHMDS as a base to get moderate yields. The reaction has been screened in various bases followed by solvents and a gram scale reaction has also been executed under the given conditions. Based on the controll...
Read More-
Ultrasound assisted rapid synthesis of mefenamic acid based indole derivatives under ligand free Cu-catalysis: Their pharmacological evaluation
2005
An improved and rapid synthesis of mefenamic acid based indole derivatives has been achieved via the ligand free Cu-catalyzed coupling-cyclization method under ultrasound irradiation. This simple, straightforward and inexpensive one-pot method involved the reaction of a terminal alkyne derived from mefenamic acid with 2- iodosulfanilides in the presence of CuI ...
Read More -
Formal synthesis of Cladospolide C & epi-Cladospolide C using R- (þ)-g-valerolactone as a chiral synthon
2005
The formal synthesis of Cladospolide-C and its analog is achieved by using enantiopure (R)-g evalerolactone 10. The significant points of this synthesis are the stereoselective dihydroxylation of a, bunsaturated ester 16 using Sharpless protocol, Wittig olefination of g evalerolactol 6 with triphenylphosphonium iodide salt 7, one pot selective oxidation ...
Read More -
Amberlite-15 promoted an unprecedented aza Michael rearrangement for one pot synthesis of dihydroquinazolinone compounds
2005
A new one pot multicomponent annulation strategy for the synthesis of various dihydroquinazolinone compounds has been developed using Amberlite-15 as a catalyst, giving good to moderate yields. In this reaction the substrate scope for amines and aldehydes was also investigated. The reaction has been checked on a large scale ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market